This report provides comprehensive information on the therapeutic development for Gastric Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gastric Cancer and special features on late-stage and discontinued projects.
Gastric (stomach) cancer is a disease in which malignant (cancer) cells form in the lining of the stomach. Almost all gastric cancers are adenocarcinomas.
Infection with bacteria called H. pylori is a common cause of gastric cancer.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Companies discussed include: AB Science, AbbVie Inc., AbGenomics International, Inc., Advaxis, Inc., Advenchen Laboratories, LLC, Ambrx, Inc., Amgen Inc., Aslan Pharmaceuticals Pte. Ltd., Astellas Pharma Inc., AstraZeneca PLC, AVEO Pharmaceuticals, Inc., Avipep Pty Ltd, Azaya Therapeutics Incorporated, Basilea Pharmaceutica AG, Bayer AG, Bellicum Pharmaceuticals, Inc., BioMarin Pharmaceutical Inc., Biotecnol, Inc., Boehringer Ingelheim GmbH, Boston Biomedical, Inc., Bristol-Myers Squibb Company, CAM Biotherapeutics Ltd., Celgene Corporation, Cellectar Biosciences, Inc., Celltrion, Inc., Celon Pharma Sp.
z o.o., Cerulean Pharma, Inc., Chipscreen Biosciences Ltd, Chugai Pharmaceutical Co., Ltd., Covagen AG, DAE HWA Pharmaceutical Co., Ltd., Daiichi Sankyo Company, Limited, Deciphera Pharmaceuticals, LLC, DiaMedica Inc., Dong-A Socio Group, Eddingpharm, Eli Lilly and Company, Epirus Biopharmaceuticals, Inc., Esperance Pharmaceuticals, Inc., Exelixis, Inc., F. Hoffmann-La Roche Ltd., Five Prime Therapeutics, Inc., Galaxy Biotech, LLC, Galena Biopharma, Inc., Genentech, Inc., GlaxoSmithKline plc, GlycoNex Inc., Glycotope GmbH, Green Cross Corporation, Hanmi Pharmaceuticals, Co.
Ltd., Hutchison MediPharma Limited, ImmunoGen, Inc., Immunomedics, Inc., Imugene Limited, Incuron, LLC, Incyte Corporation, INSYS Therapeutics, Inc., Intezyne, Inc, ISU ABXIS Co.,Ltd., Jiangsu Hengrui Medicine Co., Ltd., Jiangsu Kanion Pharmaceutical Co., Ltd, Kadmon Corporation, LLC, Karyopharm Therapeutics, Inc., Kinex Pharmaceuticals, LLC, Kuhnil Pharmaceutical Co., Ltd., Kyowa Hakko Kirin Co., Ltd., Les Laboratoires Servier SAS, MacroGenics, Inc., Mebiopharm Co., Ltd., Merck & Co., Inc., Merck KGaA, Mersana Therapeutics, Inc., Millennium Pharmaceuticals, Inc., Molecular Targeting Technologies, Inc, MSM Protein Technologies, Inc., NanoCarrier Co., Ltd., NeoPharm Co., Ltd., Novartis AG, Omnitura Therapeutics Inc., OncoTherapy Science, Inc., Oncothyreon Inc., Ono Pharmaceutical Co., Ltd., Panacea Biotec Limited, Patrys Limited, Pfizer Inc., Pharmacyclics, Inc., Priaxon AG, Regulon Inc., Rexahn Pharmaceuticals, Inc., Richter Gedeon Nyrt., Sanofi , Sareum Holdings plc, SentoClone International AB, Sequella, Inc., Siena Biotech S.p.A., Sorrento Therapeutics, Inc., Sunesis Pharmaceuticals, Inc., Supratek Pharma Inc., Synta Pharmaceuticals Corp., Synthon Holdings BV, Taiho Pharmaceutical Co., Ltd., Tesaro, Inc., Vaxon Biotech, Zymeworks Inc.
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Gastric Cancer
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Gastric Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Complete report available @ http://www.rnrmarketresearch.com/gastric-cancer-pipeline-review-h1-2015-market-report.html .
For more information:
News From
RnR Market Research Category: Industry Reports & Market Analysis Profile: RnRMarketResearch.com is an online database of market research reports offers in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.
